Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
|Articles|April 21, 2015
KRAS and Outcomes in Pancreatic Cancer
Author(s)Mark Erlander, PhD
Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.
Advertisement
Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.
Advertisement
Related to this article
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
3
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
5